Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Controlled Clinical Trial
. 2015:2015:758314.
doi: 10.1155/2015/758314. Epub 2015 Jan 19.

Fatigue in patients with multiple sclerosis: is it related to pro- and anti-inflammatory cytokines?

Arjan Malekzadeh  1 , Wietske Van de Geer-Peeters  2 , Vincent De Groot  3 , Charlotte Elisabeth Teunissen  1 , Heleen Beckerman  3 ; TREFAMS-ACE Study Group  2
Collaborators, Affiliations
Controlled Clinical Trial

Fatigue in patients with multiple sclerosis: is it related to pro- and anti-inflammatory cytokines?

Arjan Malekzadeh et al. Dis Markers. 2015.

Abstract

Objective: To investigate the pathophysiological role of pro- and anti-inflammatory cytokines in primary multiple sclerosis-related fatigue.

Methods: Fatigued and non-fatigued patients with multiple sclerosis (MS) were recruited and their cytokine profiles compared. Patients with secondary fatigue were excluded. Fatigue was assessed with the self-reported Checklist Individual Strength (CIS20r), subscale fatigue. A CIS20r fatigue cut-off score of 35 was applied to differentiate between non-fatigued (CIS20r fatigue ≤34) and fatigued (CIS20r fatigue ≥35) patients with MS. Blood was collected to determine the serum concentrations of pro-inflammatory cytokines (IL-1β, IL-2, IL-6, IL-8, IL-12p70, IL-17, TNFα, and IFN-γ) and anti-inflammatory cytokines (IL-4, IL-5, IL-10, and IL-13). We controlled for the confounding effect of age, gender, duration of MS, disease severity, type of MS, and use of immunomodulatory drugs.

Results: Similar cytokine levels were observed between MS patients with (n = 21) and without fatigue (n = 14). Adjusted multiple regression analyses showed a single significant positive relationship, that of IL-6 with CIS20r fatigue score. The explained variance of the IL-6 model was 21.1%, once adjusted for the confounding effect of age.

Conclusion: The pro-inflammatory cytokine interleukin-6 (IL-6) may play a role in the pathophysiology of primary fatigue in patients with MS.

Trial registrations: ISRCTN69520623, ISRCTN58583714, and ISRCTN82353628.

PubMed Disclaimer

References

    1. Compston A., Coles A. Multiple sclerosis. The Lancet. 2008;372(9648):1502–1517. doi: 10.1016/S0140-6736(08)61620-7. - DOI - PubMed
    1. Milo R., Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmunity Reviews. 2010;9(5):A387–A394. doi: 10.1016/j.autrev.2009.11.010. - DOI - PubMed
    1. Crayton H. J., Rossman H. S. Managing the symptoms of multiple sclerosis: a multimodal approach. Clinical Therapeutics. 2006;28(4):445–460. doi: 10.1016/j.clinthera.2006.04.005. - DOI - PubMed
    1. van Kessel K., Moss-Morris R. Understanding multiple sclerosis fatigue: a synthesis of biological and psychological factors. Journal of Psychosomatic Research. 2006;61(5):583–585. doi: 10.1016/j.jpsychores.2006.03.006. - DOI - PubMed
    1. Kos D., Kerckhofs E., Nagels G., D'hooghe M. B., Ilsbroukx S. Review article: origin of fatigue in multiple sclerosis: review of the literature. Neurorehabilitation and Neural Repair. 2008;22(1):91–100. doi: 10.1177/1545968306298934. - DOI - PubMed

Publication types

LinkOut - more resources